Charles River Laboratories International (CRL) Projected to Post Earnings on Thursday

Key Points

• Q1 2026 earnings on May 7: Charles River is set to report before the open on May 7, with analysts forecasting $1.93 EPS and $979.33M revenue, and the company guiding FY2026 EPS of 10.70–11.20.
• In the last quarter CRL posted $2.39 EPS, beating estimates, but revenue was down 0.8% year‑over‑year and the company reported a negative net margin of 3.59%.
• Wall Street rates CRL as a "Moderate Buy" with an average target of $205.36 while the stock trades near $163.71 (52‑week range $113.89–$228.88) and about 98.9% of shares are held by institutions.

Charles River Laboratories International (NYSE:CRL - Get Free Report) is anticipated to release its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Charles River Laboratories International to post earnings of $1.93 per share and revenue of $979.3340 million for the quarter. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. Interested persons may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:30 AM ET.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.33 by $0.06. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The business had revenue of $994.23 million during the quarter, compared to analyst estimates of $986.98 million. During the same quarter in the previous year, the company posted $2.66 earnings per share. Charles River Laboratories International's revenue for the quarter was down .8% on a year-over-year basis. On average, analysts expect Charles River Laboratories International to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $163.71 on Thursday. The stock has a 50-day simple moving average of $169.72 and a two-hundred day simple moving average of $183.10. Charles River Laboratories International has a 52-week low of $113.89 and a 52-week high of $228.88. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.02 and a current ratio of 1.29. The firm has a market capitalization of $8.08 billion, a PE ratio of -55.31, a P/E/G ratio of 2.07 and a beta of 1.61.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Wall Street Zen downgraded Charles River Laboratories International from a "buy" rating to a "hold" rating in a research report on Saturday, February 21st. Robert W. Baird set a $193.00 price objective on Charles River Laboratories International in a research report on Thursday, February 19th. Barclays boosted their price objective on Charles River Laboratories International from $200.00 to $210.00 and gave the company an "overweight" rating in a research report on Tuesday, April 14th. UBS Group boosted their price objective on Charles River Laboratories International from $170.00 to $175.00 and gave the company a "neutral" rating in a research report on Wednesday, February 25th. Finally, Evercore restated an "outperform" rating on shares of Charles River Laboratories International in a research report on Wednesday, April 8th. Eleven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $205.36.

Hedge Funds Weigh In On Charles River Laboratories International

Large investors have recently made changes to their positions in the business. Jones Financial Companies Lllp lifted its position in shares of Charles River Laboratories International by 167.6% in the first quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company's stock worth $253,000 after buying an additional 1,074 shares in the last quarter. Metis Global Partners LLC purchased a new stake in shares of Charles River Laboratories International in the fourth quarter worth about $213,000. DRW Securities LLC purchased a new stake in shares of Charles River Laboratories International in the fourth quarter worth about $211,000. Humankind Investments LLC purchased a new stake in shares of Charles River Laboratories International in the second quarter worth about $210,000. Finally, Suvretta Capital Management LLC purchased a new stake in shares of Charles River Laboratories International in the fourth quarter worth about $201,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.